Dog Hair Extract Study

NCT ID: NCT01343420

Last Updated: 2021-01-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Liquid allergen extracts contain proteins, such as (but not limited to) tree, weed, cat, cockroach, and nuts, and are used to identify allergies by observing the body's reaction to the introduction of extract underneath the skin. There are a few dog allergen extracts commercially available in the US for allergy testing; however, none of these products are standardized, meaning they are not required to be the same strength. Because some extracts are not as potent (strong) as others, it's possible that some patients' allergies are misdiagnosed. Typically, the most potent (strong), but safe extract should be used so that allergic patients are correctly diagnosed.

The purpose of this study is to compare the safety and potency of an investigational (not approved for use by the United States Food and Drug Administration \[FDA\]) dog allergen extract with two commercially available dog extracts, which are of differing potencies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed to assess the potency of a modified dog hair and dander extract in comparison with the two commercially available dog hair and dander extracts. This is a pilot study to estimate a target strength of dog extract in order to proceed to further studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Potency of Dog Hair Extract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dog Hair Extract, ALK-Abelló, Inc.

Group Type ACTIVE_COMPARATOR

Dog Hair Extract, ALK-Abelló, Inc.

Intervention Type BIOLOGICAL

ALK-Abelló dog epithelial 1:10w/v glycerin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dog Hair Extract, ALK-Abelló, Inc.

ALK-Abelló dog epithelial 1:10w/v glycerin

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must sign informed consent before completing any study procedure.
* Age 18 years and ≤60 years.
* Dog-sensitized patients as indicated by a mean wheal \> 5 mm with the AP dog extract.
* Females of child-bearing potential must have a negative pregnancy test the day of skin testing.
* Patients who are able to understand the information given and be compliant with the protocol.

Exclusion Criteria

* Asthma requiring treatment with medications other than beta-2 inhaled agonists and montelukast inhibitors.
* Patients with a history of asthma or wheezing with an FEV1 \<80%.
* Subjects who have taken an ocular or nasal antihistamine within 5 days prior to the procedures.
* Patients who have received any desensitization for dog allergen in the past 5 years.
* Patients with any past or current clinically significant condition that may affect the patient's participation or the outcome of the study to the discretion of the investigator. These include, but are not limited to, anaphylaxis with cardio-respiratory symptoms, chronic urticaria and angioedema unless related to dog exposure, severe atopic dermatitis, malignancy, cardiovascular, hepatic, renal, hematological, neurological, immunological, and endocrine disease.
* Subjects taking beta blockers, ace inhibitors, continuous systemic corticotherapy, immunosuppressive drugs or monoamine oxidase inhibitors.
* Use of H1 antagonists, tricyclic antidepressants and phenothiazines within 5 days prior to the testing.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ALK-Abelló A/S

INDUSTRY

Sponsor Role collaborator

National Jewish Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Harold Nelson, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Jewish Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Jewish Health

Denver, Colorado, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ALK-Abelló Dog Allergen

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.